Harvard Business Review

APRIL 16, 2012

This raises the question of whether retaining strategic cash makes economic sense and should be viewed as a legitimate corporate finance tool in today's environment. Strategic cash also can be used to finance long-term reinvestment programs in the business—which is especially valuable to companies in capital-intensive industries (e.g.,

Company 13

Company Cost of Capital Finance Long-term 13

Harvard Business Review

APRIL 2, 2018

We invest billions of dollars each year in medicines, new technologies, doctors, and hospitals—all with the goal of improving health, arguably our most prized commodity. So reducing investments in low-value care services means spending less on doctors, hospitals, and other health care technologies. rawpixel/Getty Images.

Health Care 8

Health Care Insurance Pharmaceuticals Incentives 8

Harvard Business Review

JULY 4, 2017

With that in mind, I can see three potential scenarios for how Apple might play in the autonomous car market. The second play is to try to use its technological aptitude to create a vehicle that solves a particular problem. Some of them may never enter the car market, or may at least significantly delay a move toward ownership.

Transportation 9

Transportation Sports Pharmaceuticals Health Care 9

Harvard Business Review

AUGUST 3, 2012

They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves. As yet, the facts don't seem to substantiate the fears.

Licensing 12

Licensing Depreciation Pharmaceuticals Budgeting 12

Harvard Business Review

APRIL 19, 2016

Carmakers have started using 3D technology to produce parts. Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. The technology is expected to lead to reductions in the cost of employment, capital investment, shipping and inventory as well. Threat analysis.

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

OCTOBER 20, 2016

Meanwhile the Institute of International Finance forecasted net capital flows for emerging markets in 2015 would be negative for the first time since 1988. pharmaceutical company, had to abandon its $106 billion attempt to buy British drug maker AstraZeneca in the face of opposition from UK politicians.

Globalization 8

Globalization Banking Policies Politics 8

Harvard Business Review

AUGUST 23, 2012

For highly regulated sectors like finance, social media can be a legal minefield. These hurdles aren't unique to financial services — insurance, pharmaceuticals, health care and government all face regulation, to name a few examples. without any compliance process or technology in place.". The risks and penalties are real.

Compliance 15

Compliance Media Compliance Officer Policies 15

Harvard Business Review

NOVEMBER 9, 2011

COOs are relatively common in service industries such as financial services, energy, information technology and telecommunications, but in manufacturing sectors — such as automotive, chemical, and pharmaceutical companies — they are relatively rare.

COO 11

COO Sample Telecommunications Automotive 11

Harvard Business Review

AUGUST 2, 2011

In reality, each country needs the other to succeed in order to thrive — to finance growth, secure export markets, train talent, transfer technology, and more. For example, pharmaceutical firms license compounds to each other and co-promote products in different markets.

Apparel 15

Apparel Pharmaceuticals Finance Licensing 15

Harvard Business Review

MAY 1, 2013

Without adequate financing, ministries of health and even private hospitals in developing countries often don''t have the resources needed to purchase diagnostic equipment, train workers, and ensure access to appropriate treatment. Three people die every minute from tuberculosis — a treatable and largely preventable disease.

Health Care 8

Health Care ROI NGO Long-term 8

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

AUGUST 29, 2011

We discovered some of these pushes and pulls in our research for our upcoming book, Winning the War for Talent in Emerging Markets: Why Women Are the Solution. There's a sense that a woman is just working until she gets married, [that] she is not a long-term resource," said one senior finance professional. We do all of them.".

Stress 13

Stress Human Resources Pharmaceuticals Sharpe 13

Harvard Business Review

SEPTEMBER 10, 2013

A good idea faces so many obstacles en route to market today that it''s a wonder we have any innovative products at all. Corporate R&D too often focuses on refining technologies that are already in use. Finance Innovation' You know those baby sea turtles that get eaten by birds and crabs on their way from the nest to the water?

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

SEPTEMBER 10, 2013

A good idea faces so many obstacles en route to market today that it’s a wonder we have any innovative products at all. Corporate R&D too often focuses on refining technologies that are already in use. Finance Innovation Insight Center_Innovation no-intromercial' It’s like that. Five Ways to Innovate Faster.

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

SEPTEMBER 5, 2016

Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. Finally, some companies have struggled to finance their activities without payment while they work on delivering the results, limiting their ability to innovate too.

Incentives 8

Incentives Health Care Education Insurance 8

Harvard Business Review

MAY 5, 2016

But peruse some of the recent headlines about Iran , and you might wonder whether the market’s potential was overstated. However, despite a weakened economy, political tensions, market uncertainty, and the lingering effects of sanctions, Iran remains an important opportunity for multinationals in emerging markets.

Tourism 8

Tourism Banking Due Diligence Hotels 8

Harvard Business Review

JANUARY 26, 2011

Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. By the end of October in 2010, the market value of the 100 constituent stocks reached 582 billion RMB, accounting for 31% of the total market value of the Shanghai Stock Exchange's A shares.

Long-term 14

Long-term Sample Report Pharmaceuticals 14

Harvard Business Review

SEPTEMBER 13, 2011

Here are some common examples: When pharmaceutical companies announce that a new drug has been "approved," they are actually saying that their researchers made some breakthrough discoveries as far back as fifteen years ago. Financial firms that report quarterly earnings are probably jumping the gun with their results.

Short-term 14

Short-term Pharmaceuticals Long-term Maturity 14

Harvard Business Review

FEBRUARY 4, 2013

Just under 1,000 companies account for half of the world's market capitalization, Eccles notes. Breakthrough requires an end to systemic inequities by opening up processes, information - and markets. Perhaps surprisingly, two leading examples come from pharmaceutical companies. Breakthrough Finance.

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

MARCH 24, 2011

Competitors whispered that Gupta was committing the most un-McKinsey-like of sins: cutting price to get into new markets. As the stock market began to take off, though, and options rained down on corporate execs, the compensation tables began to turn, certainly for the top ranks.

McKinsey 13

McKinsey Consultative Waterman Intellectual Capital 13

Harvard Business Review

FEBRUARY 20, 2014

You can read about it in recent issues of The Economist , The New York Times , and in the book The Second Machine Age by Erik Brynjolfsson and Andrew McAfee of the Massachusetts Institute of Technology. True, emerging market countries are getting better at what they do, and even Europe is on the upswing. The arguments are familiar.

Intellectual Capital 8

Intellectual Capital Magazine Pharmaceuticals Creativity 8

Harvard Business Review

SEPTEMBER 4, 2015

We’ve found that CEOs of big pharmaceutical companies, for example, are more likely to have a background as company lawyers, salespeople, or finance managers, than one in medicine or pharmaceutical R&D. Pharmaceuticals. The data captured a 20-year period, from 1995 to 2014. Overall, it is a messy picture.

CEO 8

CEO Innovation Pharmaceuticals Merchandising 8

Harvard Business Review

OCTOBER 24, 2014

In addressing the billion-dollar adherence problem, Vitality (since acquired by NANTHEALTH ) considered the interests of the players in the diverse ecosystem, including pharmaceutical companies, retail pharmacies, and health care providers. It also took into account their roles in changing patient behavior. and design and user experience.

Productivity 8

Productivity Products Company Engineering 8

Harvard Business Review

NOVEMBER 20, 2015

He is poised to become the leader in this segment of a multi-billion dollar market. Compliance is crucial for pharmaceutical makers such as Abbott and Amgen – a “ Form 483 ” warning from an FDA inspector can shut down a drug facility in an instant and even land top executives in jail.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

DECEMBER 12, 2018

A new generation of philanthropists, whose wealth was created via entrepreneurship in technology-driven fields, has the unique opportunity to make a real difference in speeding the pace of progress in the fight against cancer. Andrew Lo, a finance professor at MIT, has been a trailblazer in this area. Luxy Images/Getty Images.

Pharmaceuticals 8

Pharmaceuticals Venture Funding Finance Development 8